Daratumumab is the first human immunoglobulin G1 (IgG1) MoAb that targets CD38 approved for use in MM with significant clinical activity in relapsed and refractory MM [112,113,114] and recently for the treatment of newly diagnosed MM patients, in combination with other novel agents such as bortezomib, thalidomide and dexamethasone for transplant eligible patients, or with lenalidomide and dexamethasone for elderly symptomatic MM patients [115]. Here, CD38 is linked to Miyoshi myopathy.